Relapsed / Refractory Multiple Myeloma
Showing 1 - 25 of >10,000
Relapsed or Refractory Multiple Myeloma Trial (Forimtamig, Carfilzomib, Daratumumab)
Not yet recruiting
- Relapsed or Refractory Multiple Myeloma
- Forimtamig
- +2 more
- (no location specified)
Sep 20, 2023
Relapsed and Refractory Multiple Myeloma Trial in Pittsburgh (Mezigdomide, Ixazomib, Dexamethasone)
Not yet recruiting
- Relapsed and Refractory Multiple Myeloma
- Mezigdomide
- +2 more
-
Pittsburgh, PennsylvaniaUPMC Hillman Cancer Center
Sep 15, 2023
Relapsed or Refractory Multiple Myeloma Trial in Tianjin (YTS104 Cells injection)
Not yet recruiting
- Relapsed or Refractory Multiple Myeloma
- YTS104 Cells injection
-
Tianjin, Tianjin, ChinaInstitute of Hematology & Blood Diseases Hospital
Jun 13, 2023
Multiple Myeloma Trial (CM313 injection)
Not yet recruiting
- Multiple Myeloma
- CM313 injection
- (no location specified)
Nov 6, 2023
Multiple Myeloma Trial in Wollongong (IBI3003)
Not yet recruiting
- Multiple Myeloma
-
Wollongong, New South Wales, AustraliaWollongong Private Hospital
Oct 18, 2023
Relapsed or Refractory Multiple Myeloma Trial (Cevostamab, Elranatamab, Tocilizumab)
Not yet recruiting
- Relapsed or Refractory Multiple Myeloma
- Cevostamab
- +2 more
- (no location specified)
Jun 22, 2023
Relapsed or Refractory Multiple Myeloma Trial in Tianjin (QLS32015)
Recruiting
- Relapsed or Refractory Multiple Myeloma
-
Tianjin, Tianjin, ChinaInstitute of Hematology & Blood Diseases Hospital
Jun 24, 2023
Relapsed Cancer, Refractory Multiple Myeloma, Multiple Myeloma Trial in Boston (Isatuximab, Belantamab mafodotin, Pomalidomide)
Not yet recruiting
- Relapsed Cancer
- +2 more
- Isatuximab
- +3 more
-
Boston, Massachusetts
- +1 more
Jun 19, 2023
Patients With Relapsed/Refractory Multiple Myeloma
Not yet recruiting
- Relapsed and Refractory Multiple Myeloma (RRMM)
- Non-Interventional
- (no location specified)
Dec 21, 2022
Multiple Myeloma in Relapse, Multiple Myeloma, Refractory Trial in Poitiers (Isatuximab, Carfilzomib, Pomalidomide)
Active, not recruiting
- Multiple Myeloma in Relapse
- Multiple Myeloma, Refractory
- Isatuximab
- +3 more
-
Poitiers, FranceCHU Poitiers
Jan 9, 2023
Refractory Multiple Myeloma, Relapsed Multiple Myeloma Trial in San Francisco (Manufactured Anti-BCMA CAR-T cells, Fludarabine,
Recruiting
- Refractory Multiple Myeloma
- Relapsed Multiple Myeloma
- Manufactured Anti-BCMA CAR-T cells
- +2 more
-
San Francisco, CaliforniaUniversity of California, San Francisco
Jan 6, 2023
Relapsed or Refractory Non-Hodgkin's Lymphoma, Relapsed or Refractory Multiple Myeloma Trial in Changsha (BEBT-908 for
Completed
- Relapsed or Refractory Non-Hodgkin's Lymphoma
- Relapsed or Refractory Multiple Myeloma
- BEBT-908 for injection
-
Changsha, Hunan, ChinaHunan Cancer Hospital
Oct 9, 2023
Multiple Myeloma Trial in Paris (Idecabtagene vicleucel, Not treated)
Active, not recruiting
- Multiple Myeloma
- Idecabtagene vicleucel
- Not treated
-
Paris, FranceDESCAR-T Registry
Nov 27, 2023
Relapsed or Refractory Multiple Myeloma Trial in Beijing, Guangzhou, Hangzhou (STI-6129)
Not yet recruiting
- Relapsed or Refractory Multiple Myeloma
- STI-6129
-
Beijing, Beijing, China
- +3 more
Jan 9, 2023
Multiple Myeloma Trial in Orange, Sacramento, Oklahoma City (STI-1492)
Recruiting
- Multiple Myeloma
- STI-1492
-
Orange, California
- +2 more
Jan 12, 2023
Relapsed or Refractory Multiple Myeloma Trial in Canada, United States (mRNA-2736)
Not yet recruiting
- Relapsed or Refractory Multiple Myeloma
- mRNA-2736
-
Birmingham, Alabama
- +12 more
Jun 15, 2023
Multiple Myeloma Trial in Boston, Milwaukee (CART-ddBCMA)
Not yet recruiting
- Multiple Myeloma
- CART-ddBCMA
-
Boston, Massachusetts
- +1 more
Jul 7, 2022
Relapsed/Refractory Multiple Myeloma Trial (AMG 701)
Not yet recruiting
- Relapsed/Refractory Multiple Myeloma
- AMG 701
- (no location specified)
Jun 6, 2022
Multiple Myeloma Trial in Xuzhou (anti-BCMA/GPRC5D CAR-T CELL)
Recruiting
- Multiple Myeloma
- anti-BCMA/GPRC5D CAR-T CELL
-
Xuzhou, Jiangsu, ChinaKailin Xu
Aug 19, 2022